Study of Suramin in Subjects With Furosemide-Resistant AKI

Summary

This is a prospective, double-blind, randomized, placebo-controlled study to assess the effects of suramin as a potential treatment option to prevent subjects with AKI from progressing to Kidney Disease Improving Global Outcomes (KDIGO) Stage III or dialysis dependent AKI.

Timeline

Start

2020-11-13

Primary completion

2023-04-17

Completion

2023-12-22

Drugs

Indications